Deprecated: Creation of dynamic property cls_session::$session_data_table is deprecated in /www/sites/www.188bio.com/index/systems/cls_session.php on line 49
Sengenics/CTA Array/5 slides/33000188bio精品生物—专注于实验室精品爆款的电商平台 - 蚂蚁淘旗下精选188款生物医学科研用品
您好,欢迎您进入188进口试剂采购网网站! 服务热线:4000-520-616
蚂蚁淘商城 | 现货促销 | 科研狗 | 生物在线
产品资料

Sengenics/CTA Array/5 slides/33000

CTA Array

Product Number 33000

Pricing

CodeProduct Description
33000CTA Array Kit

Request a Quote

scienceexchange.com

Description

KREX™-based protein array for high-throughput quantification of autoantibodies to Cancer-Testis (CT) antigens. CT antigens are a group of unrelated proteins that show highly restricted expression profiles in adult somatic tissues but which are aberrantly expressed in various cancers.

Key applications:

  1. Unique differential profiling of cancer-antigen in various cancer types
  2. Patient stratification in checkpoint inhibitor studies
  3. Determination of epitope recognition in patients or monitor patients in experimental cancer vaccine studies

BROCHURE

APPLICATIONS

Specifications

Product name: CTA Array

Minimum Order : 5 slides

Slide Type: Streptavidin-coated glass slide

Species: Human

Storage: Store for up to 12 months at -20°c

Delivery lead time: 4 weeks

Immunome Protein Array Protocol

Protein Array Sample Annotation Form

Protein Array Submission Form

Immunome Protein Array MSDS

ProteinList

DOWNLOADS

Resources to access our technology

FAQs

Your technical questions – answered

SOLUTIONS

One technology – endless possibilities

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

新闻动态
行业前沿
技术文章
最新产品